A message from our sponsor.

Foreign price controls aren’t the right prescription. “Most favored nation” pricing fails to lower costs for American patients and only stands to give away U.S. biopharmaceutical investments to China. Washington – Stand up for American global market leadership and advance proposals that meaningfully address barriers to patient access.